Healthcare & life sciences
November 2025 | SPECIAL REPORT: HEALTHCARE & LIFE SCIENCES
Financier Worldwide Magazine
November 2025 Issue
Q&A: M&A in the healthcare and life sciences sector
Despite broader market volatility because of economic and political challenges, healthcare and life sciences remain among the most resilient sectors for M&A. FW discusses M&A in the healthcare and life sciences sector with Frank Aquila at Sullivan & Cromwell.
The high-stakes future of healthcare consolidation and regulation
Winston & Strawn Anticipating regulatory shifts and embedding compliance into strategy allows providers to withstand pressure and turn limitations into opportunities. Maintaining regulatory vigilance in tandem with the evolution of business development goals is key to successful enterprise risk management.
Adapting to legislative and policy changes in the life sciences sector
Ropes & Gray LLP Legislative and policy changes are rapidly transforming the healthcare and life sciences sectors, presenting both challenges and opportunities. Organisations that maintain a strong awareness of the evolving external policy environment and respond proactively will be best positioned to foster innovation, achieve better outcomes and manage costs effectively.
Update to the European rules on advertising medicinal products
King & Spalding The upcoming changes to the current advertising rules focus on refining the existing framework and codifying CJEU case law. None is revolutionary, but EU countries will have to adapt their national legislation, and pharmaceutical companies will have to update their materials, training and practices.
Recognition of the subjectivity of the concepts of personal data and pseudonymisation
Fieldfisher The Court of Justice of the European Union ruled on the concept of ‘pseudonymisation’, endorsing a subjective approach to assessing the identifiability of a data subject. This opens new perspectives for data reuse, particularly in the health sector, where secondary use is essential for both research and innovation.
Why intellectual property due diligence matters
Stratagem IPM Limited For finance professionals interested in funding or acquiring innovative businesses, understanding the IP strategy and verifying the IP portfolio is essential during the deep dive into a target’s affairs. Properly considering IP during the process not only mitigates risks but can also uncover opportunities that enhance deal value.
Q&A: Drug and medical device litigation
The direction of the FDA and other federal agencies may lead to increased litigation as to vaccines and other medical products that have long been considered safe and effective. FW discusses drug and medical device litigation with Christian Di Mauro at Hogan Lovells Studio Legale, Eric Alexander at Holland & Knight LLP and Alison Dennis at Taylor Wessing.
CONTRIBUTORS
Fieldfisher
Hogan Lovells Studio Legale
Holland & Knight LLP
King & Spalding
Ropes & Gray LLP
Stratagem IPM Limited
Sullivan & Cromwell
Taylor Wessing
Winston & Strawn